InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

Current share price for OCC : $0.670 0.025 (3.88%)+

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$183 Orthocell Receives $3.0m R&D Tax Refund 18 Feb 2026 12:56PM $0.930 $0.670 fallen by 27.96%
$183 US Market and Operational Update 2 Feb 2026 9:02AM $0.920 $0.670 fallen by 27.17%
$183 Orthocell Investor Webinar Details 29 Jan 2026 10:21AM $0.870 $0.670 fallen by 22.99%
$183 Quarterly Activity Report & Appendix 4C 19 Jan 2026 9:07AM $1.000 $0.670 fallen by 33%
$183 Orthocell Finalises Strategic Investment in Marine Biomedica 16 Jan 2026 9:01AM $1.015 $0.670 fallen by 33.99%
$183 Orthocell Posts Seventh Straight Record Revenue Quarter 6 Jan 2026 9:33AM $1.095 $0.670 fallen by 38.81%
$183 Appendix 3Y - Paul Anderson 22 Dec 2025 6:10PM $1.045 $0.670 fallen by 35.89%
$183 Cleansing Notice 22 Dec 2025 6:06PM $1.045 $0.670 fallen by 35.89%
$183 Application for quotation of securities - OCC 22 Dec 2025 6:04PM $1.045 $0.670 fallen by 35.89%
$183 Orthocell Hits US Milestone - 100 Remplir Units Sold. 18 Dec 2025 9:42AM $1.025 $0.670 fallen by 34.63%
$183 Remplir Regulatory Application for US$750m EU-UK Market 15 Dec 2025 9:05AM $1.020 $0.670 fallen by 34.31%
$183 First Commercial Sales of Remplir Achieved in Hong Kong 10 Dec 2025 9:18AM $1.015 $0.670 fallen by 33.99%
$183 Appendix 3Y - Paul Anderson 28 Nov 2025 6:28PM $1.070 $0.670 fallen by 37.38%
$183 Notification regarding unquoted securities - OCC 28 Nov 2025 6:24PM $1.070 $0.670 fallen by 37.38%
$183 Remplir gains momentum in nerve-sparing prostate surgery 20 Nov 2025 9:03AM $1.005 $0.670 fallen by 33.33%
$183 Cleansing Notice 14 Nov 2025 1:24PM $1.065 $0.670 fallen by 37.09%
$183 Application for quotation of securities - OCC 14 Nov 2025 1:20PM $1.065 $0.670 fallen by 37.09%
$183 Amended Constitution 6 Nov 2025 6:25PM $1.145 $0.670 fallen by 41.48%
$183 Results of Annual General Meeting 6 Nov 2025 2:50PM $1.143 $0.670 fallen by 41.36%
$183 AGM Addresses by Chair and Managing Director 6 Nov 2025 9:30AM $1.130 $0.670 fallen by 40.71%
$183 2nd Distributor in Canada, Entire $75m Market Now Covered 5 Nov 2025 8:59AM $1.160 $0.670 fallen by 42.24%
$183 Remplir Launches in Hong Kong with First Surgical Case 3 Nov 2025 9:12AM $1.165 $0.670 fallen by 42.49%
$183 Appendix 3Y - Michael McNulty 31 Oct 2025 9:03AM $1.135 $0.670 fallen by 40.97%
$183 Appendix 3Y - John Van Der Wielen 31 Oct 2025 8:59AM $1.135 $0.670 fallen by 40.97%
$183 HK Distributor Signed as Remplir Expands in the Asian Market 29 Oct 2025 8:57AM $1.120 $0.670 fallen by 40.18%

51 - 75 of 772 results

Page 3 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.